In a surprising move, President Trump has announced a 100% tariff on branded pharmaceutical products, causing a modest decline in drugmakers' shares. This decision spares most generic imports, which could have significant implications for the pharmaceutical industry and consumers alike. The tariff aims to address pricing issues but raises concerns about access to essential medications and the potential impact on healthcare costs.

President Trump's proposed 100% tariff on branded and patented drugs is raising alarms in the pharmaceutical industry, particularly for companies lacking US manufacturing capabilities. This move could significantly increase costs for these firms, putting additional pressure on them to establish domestic production. The implications of this tariff could reshape the landscape of drug manufacturing in the US, affecting prices and availability for consumers.